Lucid Diagnostics (LUCD) announced it performed a record number of commercial EsoGuard Esophageal DNA Tests during the fourth quarter of 2024. The preliminary total of 4,042 tests, the highest quarterly test volume in the company’s history, represents a sequential increase of 45% from the third quarter 2024 and an annual increase of 84% from the fourth quarter of 2023, demonstrating continued growing demand for EsoGuard esophageal precancer testing.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics granted 180-day extension by Nasdaq to regain compliance
- Lucid Diagnostics partners for esophageal precancer detection for firefighters
- Lucid announces publication on EsoGuard in peer-reviewed journal Medicina
- Lucid Diagnostics completes convertible debt refinancing
- Lucid Diagnostics’ Strategic Financial Maneuvering and Agreements